首页膀胱肿瘤诊断证据详情

尿路上皮癌相关 1 基因在膀胱癌诊断中的 Meta 分析

原文: 2017 年 发布于 BJU Int 浏览量:171次

作者: 罗晓莉 崔兆磊 陈燕

作者单位: 湖北省中医院肿瘤科 武汉大学中南医院循证与转化医学中心 华中科技大学同济医学院附属协和医院肿瘤中心 武汉科技大学医学院护理系 武汉大学中南医院泌尿外科

归属分类: 膀胱肿瘤诊断证据

DOI: 10.4103/jcrt.jcrt_608_22

文献简介

BACKGROUND: Bladder-sparing treatment of muscle invasive bladder cancer (MIBC) with systemic chemotherapy plus transurethral resection of bladder tumors (TURBT) is increasingly seen in the literature -both in case series and subanalyses of patients who opt out of or are unfit for radical cystectomy (RC). Survival outcomes among these patients are often impressive, but these are typically small retrospective studies from single institutions and therefore of limited clinical value. OBJECTIVES: Our aim is to summarize the literature regarding definitive treatment of MIBC with systemic chemotherapy plus TURBT and provide a meta-analysis of survival outcomes for patients who received this treatment. METHODS: A systematic literature search was performed consistent with the Prisma statement to identify publications reporting the outcomes of patients treated with TURBT and systemic chemotherapy as definitive treatment for locally confined MIBC. Identified studies were screened in a two-stage process: first by title and abstract; then by full-text reading. 18 publications (518 patients) were included in the qualitative systematic review and 10 publications (266 patients) were included in the meta-analysis. The primary objective was overall survival (OS). RESULTS: Overall survival ranged from 20% to 87.5% across studies at median follow-up ranging 4 to 120 months. 5-year survival rate for all patients included in the meta-analysis was estimated to be 72% [95% CI: 64%, 82%]. CONCLUSIONS: Definitive treatment with systemic chemotherapy plus TURBT can lead to favorable survival outcomes in select patients. Further study to improve patient selection for this method of treatment is needed.

热门文献